Novo Nordisk’s MASH Green Light Fuels Rally, But Overbought Signals and Conditional Approval Temper Outlook
Published on 07/05/2026 at 14:41 | Redaktion boerse-global.de
The recent surge in Novo Nordisk shares — nearly 20% over the past 30 days — has been powered by a single catalyst: the UK’s conditional approval of Wegovy for the liver disease MASH. Yet beneath the surface, technical warning lights are flashing, and the approval itself comes with strings attached that could slow the commercial payoff.
On Friday, the stock slipped 1.20% to close at €43.50, still leaving it up 3.12% for the week. The rally has been so sharp that the 14-day relative strength index now stands at 71.2, firmly in overbought territory. The shares trade more than 12% above their 50-day moving average of €38.72 and roughly 6.6% above the 200-day average of €40.80 — unusually wide spreads that leave little room for error if profit-taking sets in.
The recovery from the 52-week low of €30.25, hit on 2 March 2026, has been dramatic. But context matters: the stock still sits nearly 29% below its 52-week high of €61.20 from July 2025. Over the past twelve months, Novo Nordisk has shed 25.92%, and year-to-date it remains down 2.64%.
Conditional approval, uncertain uptake
Britain’s Medicines and Healthcare products Regulatory Agency granted Wegovy a conditional licence for MASH on 3 July 2026, allowing use of semaglutide in patients with moderate to advanced liver fibrosis. But the nod is provisional — Novo Nordisk must submit additional data from an ongoing study before full marketing authorisation can be obtained.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Crucially, the approval does not guarantee patient access. The National Institute for Health and Care Excellence (NICE) is now assessing whether the treatment is both clinically and cost-effective for the NHS. Only after NICE’s verdict will Wegovy actually reach MASH patients in the UK, meaning real-world revenue from this indication remains months or years away.
Analyst divide deepens
The mixed signals are echoed by the analyst community. DNB Carnegie lowered its price target from 430 to 420 Danish kroner while maintaining a buy rating — a gesture of long-term faith tempered by near-term caution. Across the Atlantic, US-based analysts are more cautious, leaning toward hold recommendations and setting lower targets. This transatlantic split underscores the uncertainty surrounding Novo Nordisk’s ability to defend its position in the critical US obesity market against Eli Lilly, which is racing to push its own GLP-1 drugs into the same disease areas.
Beyond weight loss: cancer prevention
While the market digests the MASH news, a study published in JAMA Network Open has broadened the horizon for GLP-1 therapies. Analysing medical records of 1.6 million patients, researchers found that drugs like semaglutide reduced the risk of 10 out of 13 obesity-related cancers — including oesophageal, colorectal and kidney cancer — compared with traditional insulin therapy. For Novo Nordisk, the finding opens a potential revenue stream far beyond diabetes and weight management, though clinical validation and regulatory pathways are still early.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Production bottleneck looms
Meeting demand for an expanding list of indications will test Novo Nordisk’s manufacturing muscle. A new $360 million plant in Bohumil, Czech Republic, began production at the end of June, focusing on carrier proteins for next-generation diabetes and obesity drugs. Meanwhile, Novo Holdings is ploughing more than €2 billion into Italian manufacturing sites through its acquisition of contract manufacturer Catalent, with investments running through 2029.
The key technical level to watch in the coming week is the €40 mark, which aligns almost exactly with the 200-day moving average. A break below that could trigger further selling from momentum-driven investors looking to lock in gains after the 20% monthly run. How institutions respond to the overbought condition — and how quickly NICE rules on NHS coverage — will determine whether the rally has legs or needs a breather.
Ad
Novo Nordisk Stock: New Analysis - 5 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
